retatrutide 2 mg Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide | True Peptides

Some participants in early studies experienced slight increases in heart rate or mild rhythm disturbances

In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in blood pressure Favourable changes in lipid profiles Reductions in fasting glucose and insulin resistance Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk

Unlike other weight-loss injections, retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, whereas typical injections target one or two of these receptors

However, clinical consideration is still required

Think of peptides as your bodys tiny messengers

Retatrutide is being studied in metabolic, adipose, and hepatic research models